Clinical Trials Directory

Trials / Terminated

TerminatedNCT04104594

Olfaction and Inflammation in Chronic Rhinosinusitis With Nasal Polyps

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
3 (actual)
Sponsor
Centre Hospitalier Universitaire de Saint Etienne · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Impaired olfaction is one of the major complaints of patients with nasosinus polyposis, with nasal obstruction. In case of failure of medical treatment for patients with polyposis nasosinusal, they may use endoscopic surgery nasosinusal. Before surgery, 73% are hyposmic or anosmic, compared to 43% after surgery. Persistence of hyposmia or anosmia despite the removal of polyps can be explained by mechanisms inflammatory in the mucous membrane of the olfactory cleft. In addition, studies in mice have shown a degeneration of primary olfactory neurons at the level of the olfactory mucosa in connection with directly with TNF alpha, a pro-inflammatory molecule.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTSniffin Stick TestThe test consists of odorous rods that are presented to the patient's nose. It consists of 3 parts different, with 3 sets of corresponding sticks: an olfactory threshold test, an olfactory discrimination test and an olfactory identification test. The final score, out of 48, is the sum of the olfactory threshold, discrimination and identification scores. Normal test values are defined as greater than the tenth percentile of the general population, so the test result is compared to reference values on a chart to determine whether the patient is normosmic, hyposmic or anosmic.
OTHERnumerical evaluation scale for olfactionnumerical rating scale from 0 (no smell) to 10 (perfect smell)
OTHERnumerical evaluation scale for nasal obstructionnumerical rating scale from 0 (no freedom of the nasal passages) to 10 (maximum nasal freedom)
OTHERnasal outcome testlist of symptoms and social/emotional consequences of rhino-sinusitis. 16 questions that the patient must code from "no problem" to "serious problem" over the last 15 days
BIOLOGICALdosage of 17 cytokinesdosage of 17 cytokines : G-CSF, GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, MCP-1 (MCAF), MIP-1β,TNF-α

Timeline

Start date
2020-02-05
Primary completion
2021-07-06
Completion
2021-07-29
First posted
2019-09-26
Last updated
2022-10-25

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04104594. Inclusion in this directory is not an endorsement.